Incretine e diabete nuove opportunità terapeutiche
MEDICINA
12-07-2007 23:16
Autore: admin
Letture complessive articolo: 36963
In questo articolo viene riassunto l'effetto incretinico e vengono riportate le basi fisiopatologiche sulle quali sono stati sviluppati i nuovi farmaci antiabetici ad effetto incretinico, alcuni dei quali potrebbero rallentare o arrestare la disfunzione betacellulare.
la storia naturale del diabete mellitola disfunzione beta cellularele incretinela dipeptidil peptidasi-4nuovi farmaci e nuove speranzegli analoghi del GLP-1gli inibitori della DPP-4Bibliografia
Bibliografia
Letture di questa pagina: 1994
1) Nauck MA, et al: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498. 1986
2) Rotella CM, Pala L, Mannucci E (2005) Glucagon-like peptide-1 and metabolic diseases. J Endocrinol Invest 28: 746-758.
3) Drucker DJ (2006) The biology of incretin hormones. Cell Metab3: 153-165.
4) Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipetidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
5) Prentki M, Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006 Jul;116(7):1802-12.
6) AulingerBenedikt; D'Alessio David : Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic. Current Opinion in Endocrinology, Diabetes & Obesity.14(1):68-73, February 2007
7) Lancet. 1998;352:854-65
8) Kieffer TJ, Habener JF. Endocr Rev. 1999;20:876–913
9) Kieffer TJ, Habener JF. Endocr Rev. 1999;20:876–913
10) Drucker DJ. Diabetes Care. 2003;26:2929–2940
11) Holst JJ. Diabetes Metab Res Rev. 2002;18:430–441
12) Raz I et al. Diabetologia. 2006;49:2564–2571.
13) Aschner P et al. Diabetes Care. 2006;29:2632–2637
14) Charbonnel B et al. Diabetes Care. 2006;29:2638–2643.
15) Rosenstock J et al. Clin Ther. 2006;28:1556–1568
16) Chang et al. Diabetes 2003;52: 1786–1791.
17) DeFronzo, RA, et al: Diabetes Care 27:1092-1100. 2005.
18) Ratner, RE et al: Diab Obes Metab 8: 419-428. 2006.
19) Blonde, L et al : Diab Obes Metab 8: 436-447. 2006.
20) Bartus. RT et al: Science 281: 1161-1162. 1998
2) Rotella CM, Pala L, Mannucci E (2005) Glucagon-like peptide-1 and metabolic diseases. J Endocrinol Invest 28: 746-758.
3) Drucker DJ (2006) The biology of incretin hormones. Cell Metab3: 153-165.
4) Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipetidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
5) Prentki M, Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006 Jul;116(7):1802-12.
6) AulingerBenedikt; D'Alessio David : Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic. Current Opinion in Endocrinology, Diabetes & Obesity.14(1):68-73, February 2007
7) Lancet. 1998;352:854-65
8) Kieffer TJ, Habener JF. Endocr Rev. 1999;20:876–913
9) Kieffer TJ, Habener JF. Endocr Rev. 1999;20:876–913
10) Drucker DJ. Diabetes Care. 2003;26:2929–2940
11) Holst JJ. Diabetes Metab Res Rev. 2002;18:430–441
12) Raz I et al. Diabetologia. 2006;49:2564–2571.
13) Aschner P et al. Diabetes Care. 2006;29:2632–2637
14) Charbonnel B et al. Diabetes Care. 2006;29:2638–2643.
15) Rosenstock J et al. Clin Ther. 2006;28:1556–1568
16) Chang et al. Diabetes 2003;52: 1786–1791.
17) DeFronzo, RA, et al: Diabetes Care 27:1092-1100. 2005.
18) Ratner, RE et al: Diab Obes Metab 8: 419-428. 2006.
19) Blonde, L et al : Diab Obes Metab 8: 436-447. 2006.
20) Bartus. RT et al: Science 281: 1161-1162. 1998